References
- ForghieriFLuppiMPotenzaLPhiladelphia chromosome-positive Acute Lymphoblastic LeukemiaHematology2015201061861926574786
- ChiarettiSFoàRManagement of adult Ph-positive acute lymphoblastic leukemiaHematology Am Soc Hematol Educ Program20152015140641326637750
- DombretHGabertJBoironJMOutcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia – results of the prospective multicenter LALA-94 trialBlood200210072357236612239143
- ThomasXHeibligMThe development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatmentExpert Opin Drug Discov201611111061107027548716
- LichtyBDKeatingACallumJExpression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemiaBr J Haematol199810337117159858221
- ScoreJCalasanzMJOttmanOAnalysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formationLeukemia201024101742175020703256
- RohonPDivokaMCalabkovaLIdentification of e6a2 BCR-ABL fusion in a philadelphia-positive CML with marked basophilia: Implications for treatment strategyBiomedical Papers20111552187190
- ReckelSHamelinRGeorgeonSDifferential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomicsLeukemia20173171502151228111465
- VinhasRCordeiroMPedrosaPFernandesARBaptistaPVCurrent trends in molecular diagnostics of chronic myeloid leukemiaLeuk Lymphoma20175881791180427919203
- Liu-DumlaoTKantarjianHThomasDAO’BrienSRavandiFPhiladelphia-positive acute lymphoblastic leukemia: current treatment optionsCurr Oncol Rep201214538739422669492
- LiHZhangWYiDYeYXiaoXScreening ABL1 kinase domain mutations in patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)Leuk Lymphoma20175841005100727658493
- Molinos-QuintanaAAquinoVMonteroIEmerging BCR/ABL1 mutations under treatment with tyrosine kinase inhibitors in paediatric acute lymphoblastic leukaemiaActa Haematol20151342717525895602
- PfeiferHLangeTWystubSPrevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemiaLeukemia20122671475148122230800
- NicoliniFEBasakGWKimDWOverall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutationCancer2017123152875288028387926
- SanfordDSKantarjianHO’BrienSJabbourECortesJRavandiFThe role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemiaExpert Rev Anticancer Ther201515436537325764322
- DeangeloDJStevensonKEDahlbergSELong-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemiaLeukemia201529352653425079173
- van DongenJJMacintyreEAGabertJAStandardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemiaLeukemia199913121901192810602411
- SchwarzJMCooperDNSchuelkeMSeelowDMutationTaster2: mutation prediction for the deep-sequencing ageNat Methods201411436136224681721
- ChengJRandallABaldiPPrediction of protein stability changes for single-site mutations using support vector machinesProteins200562411251132
- McguffinLJIntrinsic disorder prediction from the analysis of multiple protein fold recognition modelsBioinformatics200824161798180418579567
- KimDKimDWChoBSStructural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutationsLeuk Res20093391260126519201023